News FDA backs Curium's Bexlutry as 1st 'radioligand equivalent' Curium's copycat version of Novartis GEP-NET therapy Lutathera, Bexlutry, is the first radioligand equivalent (RLE) to be approved by the FDA.
News GSK wagers $750m on Chimagen multiple myeloma therapy GSK has continued a drive to bulk up its pipeline, taking global rights to a T-cell engager for multiple myeloma, developed by China's Chimagen Bio.
News WCLC: Lung cancer news from BioNTech, Akeso, and Roche As the World Conference on Lung Cancer (WCLC) draws to a close, here are some late-breaking clinical trial data that made waves at the congress.
News GSK showcases positive data with lung cancer drugs at WCLC New data at WCLC26 could push GSK's ROS1+ NSCLC drug Jideytro into the first-line setting, while B7-H3-targeted ADC ris-rez extends survival in SCLC.
News AZ's Etcamah falls short in first-line breast cancer trial A week after getting FDA approval for frontline breast cancer treatment, AstraZeneca's Etcamah missed the mark in a trial aiming to expand its label.
Oncology How today’s biotechs are helping us Stand Up To Cancer In recognition of Stand Up To Cancer Day, a look at next-generation treatments that are on the verge of making it into clinical practice.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.